Cat. No.: HY-103666

CY-09

51 Cited Publications

Avis client

Based on 51 publication(s) in Google Scholar

CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.01%
CAS No.: 1073612-91-5
Formule: C₁₉H₁₂F₃NO₃S₂
Masse moléculaire:423.43

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

CY-09 Chemical Structure

CAS No.: 1073612-91-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (51)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

NLRP3

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR) :

In Vitro

CY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 μM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 specifically inhibits NLRP3 inflammasome activation and has no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

CY-09 treatment in vivo efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation in vivo. CY-09 treatment also increases the survival of NLRP3 mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of high-fat diet (HFD)-treated mice is also suppressed by CY-09^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1073612-91-5
Appearance Solid
Masse moléculaire 423.43
Formule C₁₉H₁₂F₃NO₃S₂
Color Light yellow to yellow
SMILES

OC(C1=CC=C(/C=C2SC(N(CC3=CC=CC(C(F)(F)F)=C3)C\2=O)=S)C=C1)=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (51)

All WBRT-PCRELISAFlow CytometryIF

Sort by:

Journal Impact Factor

Cell Res

Signal-induced NLRP3 phase separation initiates inflammasome activation. [Abstract]

2025 Apr 1. PMID: 40164768

CY-09 purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Apr 1. [Abstract]

CY-09 (20 μM; 30 min) blocked NLRP3 inflammasome activation in THP-1 cells.

CY-09 purchased from MedChemExpress. Usage Cited in: Cell Res. 2025 Apr 1. [Abstract]

CY-09 (20 μM; 30 min) suppressed NLRP3 activation induced by 1,5-PD and 1,2-PD in THP-1 cells.
Exploration

A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors. [Abstract]

2025 Dec 18;5(6):20240396. PMID: 41476656
Blood

The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. [Abstract]

2020 Jul 23;136(4):501-515. PMID: 32291445

CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]

CY-09 (1 μM; 24 h) suppressed TMAO-induced mRNA expression of M1 signature cytokines or chemokines in BMDMs, including IL-1β, IL-6, TNF-α, CXCL9, and CXCL10.

CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]

CY-09 (1 μM; 24 h) markedly decreased the concentrations of IL-1β in the supernatant of BMDMs.

CY-09 purchased from MedChemExpress. Usage Cited in: Blood. 2020 Jul 23;136(4):501-515. [Abstract]

CY-09 (1 μM; 24 h). Flow cytometry analysis of FLICA Casapse-1 in BMDMs was determined.
Bioact Mater

An intelligent nanoreservoir system promotes heart valve regeneration via ROS scavenging and immunomodulation. [Abstract]

2025 Sep 19:55:205-223. PMID: 41035431
Nat Commun

African swine fever virus B66L drives extracellular mitochondrial release to promote systemic inflammation in mice. [Abstract]

2026 May 27. PMID: 42203763
Nat Commun

Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18. [Abstract]

2025 Jul 2;16(1):6074. PMID: 40603850
Nat Commun

Clustering of NLRP3 induced by membrane or protein scaffolds promotes inflammasome assembly. [Abstract]

2025 May 27;16(1):4887. PMID: 40425567
Mol Biomed

ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity. [Abstract]

2025 Nov 13;6(1):108. PMID: 41231359
Chem Eng J

1 May 2022, 135115.
Engineering

2025 Aug 14.
Pharmacol Res

Cardiac fibroblast-derived mitochondria-enriched sEVs regulate tissue inflammation and ventricular remodeling post-myocardial infarction through NLRP3 pathway. [Abstract]

2025 Apr:214:107676. PMID: 40015386
Cancer Lett

FABP4 in macrophages facilitates obesity-associated pancreatic cancer progression via the NLRP3/IL-1β axis. [Abstract]

2023 Oct 28:575:216403. PMID: 37741433
Cell Commun Signal

IL-1β mediates Candida tropicalis-induced immunosuppressive function of MDSCs to foster colorectal cancer. [Abstract]

2024 Aug 21;22(1):408. PMID: 39164774
Int J Biol Macromol

Chlorogenic acid mitigates heat stress-induced oxidative damage in bovine mammary epithelial cells by inhibiting NF-κB-mediated NLRP3 inflammasome activation via upregulating the Nrf2 signaling pathway. [Abstract]

2025 Apr:301:140133. PMID: 39842566
Free Radic Biol Med

Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis. [Abstract]

2022 Mar:181:29-42. PMID: 35101564
Cell Rep

Aryl hydrocarbon receptor-induced activation of AIM2 inflammasome is mediated by MOMP and MPT: A vital therapeutic pathway for inflammation. [Abstract]

2025 Dec 10;44(12):116673. PMID: 41385364
Br J Pharmacol

Cathelicidin-related antimicrobial peptide protects against ischaemia reperfusion-induced acute kidney injury in mice. [Abstract]

2020 Jun;177(12):2726-2742. PMID: 31976546
Atherosclerosis

RhoGDI3 at the trans-Golgi network participates in NLRP3 inflammasome activation, VSMC phenotypic modulation, and neointima formation. [Abstract]

2023 Dec:387:117391. PMID: 38029612
Atherosclerosis

Blocking the NLRP3 inflammasome reduces osteogenic calcification and M1 macrophage polarization in a mouse model of calcified aortic valve stenosis. [Abstract]

2022 Apr:347:28-38. PMID: 35299058
Front Immunol

NLRP3 Inflammasome Activation of Mast Cells by Estrogen via the Nuclear-Initiated Signaling Pathway Contributes to the Development of Endometriosis. [Abstract]

2021 Sep 22:12:749979. PMID: 34630429
Neurosci Bull

Single-Cell Sequencing Reveals Circadian Sensitivity of Noise-Induced Hearing Loss Mediated by Macrophage-Driven NLRP3 Inflammasome Activation. [Abstract]

2025 Jul 20. PMID: 40684422
Neurosci Bull

Macrophage-NLRP3 Inflammasome Activation Exacerbates Cardiac Dysfunction after Ischemic Stroke in a Mouse Model of Diabetes. [Abstract]

2020 Sep;36(9):1035-1045. PMID: 32683554
Ecotoxicol Environ Saf

DBP exposure induces thyroid inflammatory impairment through activating AKT/NF-κB/NLRP3 signaling. [Abstract]

2023 Oct 1:264:115385. PMID: 37625334
Cell Mol Life Sci

B.uniformis IM01-derived IAA alleviates asthma via AhR/NLRP3 pathways in mice. [Abstract]

2025 Nov 6;82(1):388. PMID: 41196415
Life Sci

Enhanced oxidative stress aggravates BLM-induced pulmonary fibrosis by promoting cellular senescence through enhancing NLRP3 activation. [Abstract]

2024 Dec 1:358:123128. PMID: 39393575
Eur J Pharmacol

Steroid constituents of Solidago canadensis alleviate LPS-induced inflammation via AMPK regulated mitophagy/NLRP3 and NF-κB pathway. [Abstract]

2025 Jul 5:998:177512. PMID: 40113066
Int J Mol Sci

HERV-W Env Induces Neuron Pyroptosis via the NLRP3-CASP1-GSDMD Pathway in Recent-Onset Schizophrenia. [Abstract]

2025 Jan 9;26(2):520. PMID: 39859234
Int Immunopharmacol

Candida tropicalis induces NLRP3 inflammasome activation via glycogen metabolism-dependent glycolysis and JAK-STAT1 signaling pathway in myeloid-derived suppressor cells to promote colorectal carcinogenesis. [Abstract]

2022 Dec;113(Pt B):109430. PMID: 36384075

CY-09 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2022 Dec;113(Pt B):109430. [Abstract]

CY09 remarkably inhibits the infiltration of CD11b⁺ myeloid cells in colon tumors of C. tropicalis-gavaged CAC mice.
Int Immunopharmacol

Protective effect of ginsenoside Rh2 against Toxoplasma gondii infection-induced neuronal injury through binding TgCDPK1 and NLRP3 to inhibit microglial NLRP3 inflammasome signaling pathway. [Abstract]

2022 Nov:112:109176. PMID: 36067653
Mol Neurobiol

Isobavachalcone's Alleviation of Pyroptosis Contributes to Enhanced Apoptosis in Glioblastoma: Possible Involvement of NLRP3. [Abstract]

2022 Nov;59(11):6934-6955. PMID: 36053436
Inflammation

METTL3 Modulates TXNIP Expression to Affect the Activation of NLRP3 Inflammasome in Hepatic Cells Under Oxygen-Glucose Deprivation/Reperfusion Injury. [Abstract]

2024 Jun;47(3):1028-1040. PMID: 38236385
Sci Rep

Molecular and spatial heterogeneity of macrophage like vascular smooth muscle cells in abdominal aortic aneurysms associated with intraluminal thrombus. [Abstract]

2026 Mar 16;16(1):13654. PMID: 41839967
Eur J Med Res

Identification of the pyroptosis, apoptosis, and necroptosis (PANoptosis) involved in osteogenic differentiation inhibition impaired by tumor necrosis factor-α. [Abstract]

2025 Jul 1;30(1):541. PMID: 40597297
Environ Toxicol Pharmacol

Construction of a toxicity pathway from activation of the TLR4/NF-κB/NLRP3 axis to Parkinson's disease-like non-motor symptoms in mice. [Abstract]

2025 Jun:116:104706. PMID: 40306475
J Inflamm Res

Chinese Herbal Medicine Suyin Detoxification Granule Inhibits Pyroptosis and Epithelial-Mesenchymal Transition by Downregulating MAVS/NLRP3 to Alleviate Renal Injury. [Abstract]

2021 Dec 7;14:6601-6618. PMID: 34908861
iScience

Excipient of paclitaxel induces metabolic dysregulation and unfolded protein response. [Abstract]

2021 Sep 25;24(10):103170. PMID: 34646996
J Virol

Avian coronavirus IBV-induced activation of the NLRP3-Caspase-1-IL-1β axis in renal collecting ducts contributes to nephropathogenesis. [Abstract]

2025 Dec 23;99(12):e0146625. PMID: 41334910
J Funct Foods

2021, 104584.
Neuromolecular Med

SP3-Mediated Transcriptional Activation of GRIK1 is Involved in Alzheimer's Disease-Induced Cognitive Decline by Inducing Inflammasome Activation in Microglia. [Abstract]

2025 Mar 7;27(1):22. PMID: 40055261
Biochim Biophys Acta Mol Cell Biol Lipids

Palmitic acid activates NLRP3 inflammasome through NF-κB and AMPK-mitophagy-ROS pathways to induce IL-1β production in large yellow croaker (Larimichthys crocea). [Abstract]

2024 Mar;1869(2):159428. PMID: 38029958
J Orthop Surg Res

Daphnoretin relieves IL-1β-mediated chondrocytes apoptosis via repressing endoplasmic reticulum stress and NLRP3 inflammasome. [Abstract]

2022 Nov 16;17(1):487. PMID: 36384642

CY-09 purchased from MedChemExpress. Usage Cited in: J Orthop Surg Res. 2022 Nov 16;17(1):487. [Abstract]

Daphnoretin or CY-09 markedly attenuates the expression of COX-2, iNOS, TNF-α, IL-6, PGE2 and the NLRP3-ASC-Caspase1 infammasome in ATDC5 cells.
Mol Immunol

CoQ10 alleviates hepatic ischemia reperfusion injury via inhibiting NLRP3 activity and promoting Tregs infiltration. [Abstract]

2023 Mar:155:7-16. PMID: 36640727
Immunopharmacol Immunotoxicol

Capillin protects against non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation and oxidative stress. [Abstract]

2021 Dec;43(6):778-789. PMID: 34618611
Vet Microbiol

PRRSV infection inhibits CSFV C-strain replication via GSDMD-mediated pyroptosis. [Abstract]

2024 Nov:298:110243. PMID: 39299011
Vet Microbiol

PRRSV inhibited the proliferation of CSFV by inducing IL-1β maturation via NLRP3 inflammasome activation. [Abstract]

2023 Sep:284:109825. PMID: 37453262
Hum Cell

FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation. [Abstract]

2022 Nov;35(6):1752-1765. PMID: 35930135
Med Sci Monit

P2X7 Receptor (P2X7R) of Microglia Mediates Neuroinflammation by Regulating (NOD)-Like Receptor Protein 3 (NLRP3) Inflammasome-Dependent Inflammation After Spinal Cord Injury. [Abstract]

2020 Sep 21:26:e925491. PMID: 32952148
Neuroreport

NDUFC2 deficiency exacerbates endothelial mesenchymal transformation during ischemia-reperfusion via NLRP3. [Abstract]

2023 Sep 6;34(13):670-676. PMID: 37506315
Research Square Preprint

2023 Oct 11.
SSRN

2023 Sep 15.
Biomed Pharmacother

Dendrobium officinale polysaccharides attenuate uropathogenic Escherichia coli (UPEC)-induced pyroptosis in macrophage cells. [Abstract]

2022 Jul;151:113098. PMID: 35594714

Solvant et solubilité

In Vitro:

DMSO : ≥ 150 mg/mL (354.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3617 mL

11.8083 mL

23.6167 mL

5 mM

0.4723 mL

2.3617 mL

4.7233 mL

10 mM

0.2362 mL

1.1808 mL

2.3617 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water

Solubility: 1.5 mg/mL (3.54 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

For ATPase activity assay, purified recombinant human proteins are incubated at 37°C with indicated concentrations of CY-09 for 15 min in the reaction buffer. ATP (25 µm) is then added, and the mixture is further incubated at 37°C for another 40 min. The amount of ATP converted into adenosine diphosphate (ADP) is determined by luminescent ADP detection with ADP-Glo Kinase Assay kit according to the manufacturer’s protocol. The results are expressed as percentage of residual enzyme activity to the vehicle-treated enzyme. For ATP binding assay, purified NLRP3 proteins are incubated with ATP binding agarose for 1 h and then different concentrations of CY-09 are added and incubated for 2 h with motion at 4°C. Beads are washed and boiled in loading buffer. Samples are subjected to immunoblotting analysis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

To induce NLRP3 inflammasome activation, 5×10⁵/mL BMDMs and 6×10⁶/mL PBMCs are plated in 12-well plates. The following morning, the medium is replaced, and cells are stimulated with 50 ng/mL LPS or 400 ng/mL Pam3CSK4 (for noncanonical inflammasome activation) for 3 h. After that, CY-09 or other inhibitors are added into the culture for another 30 min, and then the cells are stimulated for 4 h with monosodium urate (MSU) (150 µg/mL), Salmonella typhimurium (multiplicity of infection) or for 30 min with ATP (2.5 mM) or nigericin (10 µM). Cells are transfected with poly(dA:dT) (0.5 µg/mL) for 4 h or LPS (500 ng/mL) overnight. Cell extracts and precipitated supernatants are analyzed by immunoblot^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

WT or Nlrp3^−/− mice at the age of 6 wk, with similar plasma glucose levels and body weights are randomized into different groups. For generation of high-fat diet (HFD)-induced diabetic mice, mice are fed with HFD for 14 wk. The diabetic mice are treated with CY-09 (i.p.) at a dose of 2.5 mg/kg once a day for 6 wk. The mice are maintained with HFD when used for CY-09 treatment and the subsequent experiments^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214(11):3219-3238. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3617 mL	11.8083 mL	23.6167 mL	59.0416 mL
	5 mM	0.4723 mL	2.3617 mL	4.7233 mL	11.8083 mL
	10 mM	0.2362 mL	1.1808 mL	2.3617 mL	5.9042 mL
	15 mM	0.1574 mL	0.7872 mL	1.5744 mL	3.9361 mL
	20 mM	0.1181 mL	0.5904 mL	1.1808 mL	2.9521 mL
	25 mM	0.0945 mL	0.4723 mL	0.9447 mL	2.3617 mL
	30 mM	0.0787 mL	0.3936 mL	0.7872 mL	1.9681 mL
	40 mM	0.0590 mL	0.2952 mL	0.5904 mL	1.4760 mL
	50 mM	0.0472 mL	0.2362 mL	0.4723 mL	1.1808 mL
	60 mM	0.0394 mL	0.1968 mL	0.3936 mL	0.9840 mL
	80 mM	0.0295 mL	0.1476 mL	0.2952 mL	0.7380 mL
	100 mM	0.0236 mL	0.1181 mL	0.2362 mL	0.5904 mL

Keywords

CY-09

51 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

CY-09

Covalent Screening Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Targeted Diversity Library

Antidepressant Compound Library

Heterocyclic Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Inflammasomes related Compound Library

Radioprotector Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Pattern Recognition Receptors Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Publications Citing Use of MedChemExpress (MCE) CY-09

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR)

Activité biologique

Chemical Information

Publications (51)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

CY-09

Covalent Screening Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Pyroptosis Compound Library

Targeted Diversity Library

Antidepressant Compound Library

Heterocyclic Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Inflammasomes related Compound Library

Radioprotector Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Pattern Recognition Receptors Library

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Publications Citing Use of MedChemExpress (MCE) CY-09

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR)

Activité biologique

Chemical Information

Publications (51)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

CY-09 Related Classifications

HY-103666 Related Classifications